Verrica Pharmaceuticals (VRCA) News Today $0.62 +0.02 (+3.66%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$0.62 0.00 (0.00%) As of 07:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VRCA Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Verrica Pharmaceuticals (NASDAQ:VRCA) Shares Up 0% - Here's WhyVerrica Pharmaceuticals (NASDAQ:VRCA) Trading Up 0% - Here's WhyJune 10 at 1:49 AM | marketbeat.comVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New YorkMay 28, 2025 | globenewswire.comWall Street Zen Upgrades Verrica Pharmaceuticals (NASDAQ:VRCA) to "Hold"Wall Street Zen upgraded Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday.May 24, 2025 | marketbeat.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by AnalystsVerrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has been assigned an average rating of "Hold" from the five ratings firms that are presently covering the stock, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and one has issued a buy rating onMay 24, 2025 | marketbeat.comResearch Analysts Offer Predictions for VRCA Q2 EarningsVerrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) - Equities researchers at Brookline Capital Management increased their Q2 2025 earnings estimates for Verrica Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 14th. Brookline Capital Management analystMay 20, 2025 | marketbeat.comVerrica Pharmaceuticals Reports Record Q1 Revenue and Advancements in PipelineMay 18, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q1 2025 Corporate Update Conference CallMay 13, 2025 | seekingalpha.comVerrica Pharmaceuticals Reports Quarterly 2025 Financial ResultsMay 13, 2025 | globenewswire.com6VRCA : Earnings Outlook For Verrica PharmaceuticalsMay 13, 2025 | benzinga.comVerrica Pharmaceuticals to Host Q1 2025 Earnings Call and Corporate UpdateMay 11, 2025 | msn.comVerrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025May 7, 2025 | globenewswire.comVerrica Pharmaceuticals CEO to Present at Citizens Life Sciences ConferenceMay 4, 2025 | msn.comVerrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New YorkApril 30, 2025 | globenewswire.comVerrica Pharmaceuticals (NASDAQ:VRCA) Earns Hold Rating from Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday.April 11, 2025 | marketbeat.comHC Wainwright Has Optimistic Outlook of VRCA FY2028 EarningsVerrica Pharmaceuticals Inc. (NASDAQ:VRCA - Free Report) - Stock analysts at HC Wainwright raised their FY2028 earnings estimates for shares of Verrica Pharmaceuticals in a research note issued on Tuesday, April 8th. HC Wainwright analyst O. Livnat now expects that the company will earn $0.11 perApril 11, 2025 | marketbeat.comHC Wainwright Reaffirms Neutral Rating for Verrica Pharmaceuticals (NASDAQ:VRCA)HC Wainwright reissued a "neutral" rating on shares of Verrica Pharmaceuticals in a research note on Tuesday.April 10, 2025 | marketbeat.comVerrica Pharmaceuticals Reports Strong First-Quarter Growth for YCANTHApril 9, 2025 | msn.comIn face of U.S. stock market selloff, shares of West Chester firm are on the riseApril 8, 2025 | bizjournals.comVerrica Pharmaceuticals experiences ‘strong demand-led growth’ for YCANTH in Q1April 8, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH® Dispensed Applicator Units in First Quarter 2025April 7, 2025 | markets.businessinsider.comRBC Capital Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)April 5, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Adds Dr. Gavin Corcoran to Board of DirectorsApril 4, 2025 | msn.comVerrica Pharmaceuticals Appoints Dr. Corcoran as DirectorApril 2, 2025 | tipranks.comVerrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of DirectorsApril 2, 2025 | globenewswire.comVerrica Pharmaceuticals to Present at Needham Healthcare ConferenceApril 2, 2025 | msn.comHarmony, Lungpacer, Verrica and Arbutus make C-suite hiresApril 1, 2025 | bizjournals.comVerrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comVerrica Pharmaceuticals Appoints Dr. Noah Rosenberg as Chief Medical OfficerMarch 28, 2025 | msn.comVerrica Pharmaceuticals appoints Rosenberg as CMOMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical OfficerMarch 26, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D.March 26, 2025 | globenewswire.comVerrica Pharmaceuticals Reports Q4 2024 Growth and Pipeline ProgressMarch 13, 2025 | msn.comRBC Capital Remains a Hold on Verrica Pharmaceuticals (VRCA)March 12, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comVerrica Pharmaceuticals, Inc. (VRCA) Q4 2024 Earnings Conference Call TranscriptMarch 11, 2025 | seekingalpha.comVerrica Pharmaceuticals reports Q4 EPS (24c), consensus (24c)March 11, 2025 | markets.businessinsider.comVerrica Pharmaceuticals files $150M mixed securities shelfMarch 11, 2025 | markets.businessinsider.comVerrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue EstimatesMarch 11, 2025 | msn.comVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025March 3, 2025 | globenewswire.comVerrica Pharmaceuticals CEO to Speak at TD Cowen 45th Annual Health Care ConferenceFebruary 26, 2025 | msn.comVerrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in BostonFebruary 25, 2025 | globenewswire.comVerrica Pharmaceuticals announces presentation of three posters, data on VP-315January 21, 2025 | markets.businessinsider.comVerrica reports high response rate in skin cancer studyJanuary 21, 2025 | msn.comNeedham Sticks to Their Hold Rating for Verrica Pharmaceuticals (VRCA)December 22, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Reports Progress on Molluscum Treatment and Pipeline DevelopmentDecember 20, 2024 | msn.comVerrica Provides Business and Operational UpdateDecember 20, 2024 | markets.businessinsider.comVerrica Pharmaceuticals provides update on new commerical strategy for YCANTHDecember 20, 2024 | markets.businessinsider.comVerrica Pharmaceuticals Reports Increased Demand for YCANTH with New Single Applicator Configuration Coming in 2025December 20, 2024 | quiverquant.comVerrica Pharmaceuticals Grants Stock Option to New COO David ZawitzDecember 12, 2024 | msn.com Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address VRCA Media Mentions By Week VRCA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VRCA News Sentiment▼1.150.87▲Average Medical News Sentiment VRCA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VRCA Articles This Week▼32▲VRCA Articles Average Week Get Verrica Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for VRCA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies SCPH News FDMT News NBTX News PRME News KOD News BTMD News CRGX News GNFT News CTMX News MNPR News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VRCA) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verrica Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Verrica Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VRCA Stock Free VRCA Stock Alerts